Trial Profile

Rivaroxaban vs Warfarin in Patients With Metallic Prosthesis

Status: Discontinued

Phase of Trial: Phase II/III

Latest Information Update: 11 Nov 2020

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Rivaroxaban (Primary) ; Warfarin
Indications Stroke; Thromboembolism; Transient ischaemic attacks
Focus Adverse reactions; Proof of concept; Therapeutic Use
Acronyms RIWA

Most Recent Events

05 Nov 2020 Primary endpoint has been met. (Patients with thromboembolic events: Stroke, transient ischemic attack (TIA), silent brain infarction (SBI) and systemic embolism (SE).)
05 Nov 2020 Results published in the American Journal of Cardiovascular Drugs
26 Apr 2020 Status changed from recruiting to discontinued.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com